{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:40Z","timestamp":1783741000004,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"DOI":"10.7759\/cureus.85366","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:20:38Z","timestamp":1749075638000},"source":"Crossref","is-referenced-by-count":2,"title":["Life-Threatening Ventricular Fibrillation Linked to High-Dose Tirzepatide-Induced Gastrointestinal Side Effects"],"prefix":"10.7759","author":[{"given":"Thirumala Keerthi Chandrika","family":"Kammaripalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob R","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humza","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amulya","family":"Gade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirisha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-96. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28055","article-title":"FDA approves tirzepatide as first drug for obstructive sleep apnea","volume":"333","author":"Anderer S","year":"2025","unstructured":"Anderer S. FDA approves tirzepatide as first drug for obstructive sleep apnea. JAMA. 2025, 333:656. 10.1001\/jama.2024.28055","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra A","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024, 391:1193-205. 10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker DJ","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368:1696-1705. 10.1016\/S0140-6736(06)69705-5","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller TD","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al.. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019, 30:72-130. 10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan B","year":"2013","unstructured":"Finan B, Ma T, Ottaway N, et al.. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013, 5:209ra151. 10.1126\/scitranslmed.3007218","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2012.03.014","article-title":"Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice","volume":"35","author":"Porter D","year":"2012","unstructured":"Porter D, Faivre E, Flatt PR, H\u00f6lscher C, Gault VA. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides. 2012, 35:1-8. 10.1016\/j.peptides.2012.03.014","journal-title":"Peptides"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg LS","year":"2019","unstructured":"Gasbjerg LS, Helsted MM, Hartmann B, et al.. Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes. 2019, 68:906-17. 10.2337\/db18-1123","journal-title":"Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky ER","year":"2024","unstructured":"Hankosky ER, Wang H, Neff LM, et al.. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024, 26:319-28. 10.1111\/dom.15318","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl D","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodr\u00edguez \u00c1. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022, 327:534-45. 10.1001\/jama.2022.0078","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019878377","article-title":"GLP-1 receptor agonist-induced nausea and vomiting resulting in severe hypokalemia and hospitalization: a case report","volume":"34","author":"Lohr KM","year":"2021","unstructured":"Lohr KM, Johnson E, Schmitz KH, O\u2019Brien C. GLP-1 receptor agonist-induced nausea and vomiting resulting in severe hypokalemia and hospitalization: a case report. J Pharm Pract. 2021, 34:284-7. 10.1177\/0897190019878377","journal-title":"J Pharm Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.872899","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kwon Y","year":"2022","unstructured":"Kwon Y, Wang X, Wang C, et al.. Safety and tolerability of once-weekly GLP-1 receptor agonists: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022, 13:872899. 10.3389\/fendo.2022.872899","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1463657","article-title":"Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups","volume":"15","author":"Ou Y","year":"2024","unstructured":"Ou Y, Cui Z, Lou S, et al.. Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups. Front Pharmacol. 2024, 15:1463657. 10.3389\/fphar.2024.1463657","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: the SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra R","year":"2023","unstructured":"Mishra R, Raj R, Elshimy G, et al.. Adverse events related to tirzepatide. J Endocr Soc. 2023, 7:bvad016. 10.1210\/jendso\/bvad016","journal-title":"J Endocr Soc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss JN","year":"2017","unstructured":"Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017, 10:e004667. 10.1161\/CIRCEP.116.004667","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102356","article-title":"The role of hypomagnesemia in cardiac arrhythmias: a clinical perspective","volume":"10","author":"Negru AG","year":"2022","unstructured":"Negru AG, Pastorcici A, Crisan S, Cismaru G, Popescu FG, Luca CT. The role of hypomagnesemia in cardiac arrhythmias: a clinical perspective. Biomedicines. 2022, 10:2356. 10.3390\/biomedicines10102356","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342518-life-threatening-ventricular-fibrillation-linked-to-high-dose-tirzepatide-induced-gastrointestinal-side-effects","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:20:39Z","timestamp":1749075639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342518-life-threatening-ventricular-fibrillation-linked-to-high-dose-tirzepatide-induced-gastrointestinal-side-effects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85366","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}